Who are Immunoscintigraphy with radiolabeled Cimzia®.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infliximab biosimilar, infliximab therapeutic drug monitoring, Adalimumab (Humira), Humira® (Adalimumab), Infliximab (Remicade), Akkermansia muciniphila + Infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/immunoscintigraphy-with-radiolabeled-cimzia.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Immunoscintigraphy with radiolabeled Cimzia®. — Competitive Intelligence Brief

Immunoscintigraphy with radiolabeled Cimzia®. (Immunoscintigraphy with radiolabeled Cimzia®.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiolabeled TNF-α inhibitor monoclonal antibody. Area: Immunology / Diagnostic Imaging.

phase 3 Radiolabeled TNF-α inhibitor monoclonal antibody TNF-α Immunology / Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Immunoscintigraphy with radiolabeled Cimzia®. (Immunoscintigraphy with radiolabeled Cimzia®.) — University Hospital, Ghent. Radiolabeled Cimzia (certolizumab pegol) is used as an imaging agent to visualize and localize TNF-α-expressing immune cells in inflammatory disease sites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Immunoscintigraphy with radiolabeled Cimzia®. TARGET	Immunoscintigraphy with radiolabeled Cimzia®.	University Hospital, Ghent	phase 3	Radiolabeled TNF-α inhibitor monoclonal antibody	TNF-α
Infliximab biosimilar	Infliximab biosimilar	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
infliximab therapeutic drug monitoring	infliximab therapeutic drug monitoring	Imelda GI Clinical Research Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab (Humira)	Adalimumab (Humira)	Tufts Medical Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Humira® (Adalimumab)	Humira® (Adalimumab)	Mylan Inc.	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Infliximab (Remicade)	Infliximab (Remicade)	University of California, San Diego	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiolabeled TNF-α inhibitor monoclonal antibody class)

University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Immunoscintigraphy with radiolabeled Cimzia®. — Competitive Intelligence Brief. https://druglandscape.com/ci/immunoscintigraphy-with-radiolabeled-cimzia. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab